证券代码：688617 证券简称：惠泰医疗 公告编号：2025-045 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 深圳迈瑞科技控股有限 | √ □ | 控股股东/实控人 控股股东/实控人的一致行动人 | √914403005685014490 | | 责任公司 | | | □ 不适用 | | | □ | 其他直接持股股东 | | （三）一致行动人信息 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加√ | 比例减少□ | | --- | --- | --- | | 权益变动前合计比例 | 25.00% | | | 权益变动后合计比例 | 26.54% | | | 本次变动是否违反已作出的承诺、意向、计划 | 是□ | 否√ | | 是否触发强制要约收购义务 | 是□ | 否√ | 一、信息披露义务人及其一致行动人的基本信息 （一）身份类别 | | √控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 ...

Core Viewpoint - Shenzhen Mindray Technology Holdings and its concerted party Zhuhai Tongsheng Investment increased their stake in Huatai Medical by acquiring 2.1647 million shares through block trading, raising their total shareholding from 35.2534 million shares to 37.4182 million shares, which corresponds to an increase in ownership percentage from 25.00% to 26.54% [1] Summary by Category - **Shareholding Changes** - The increase in shareholding represents 1.54% of the total share capital of Huatai Medical [1] - After the transaction, the total shares held by Shenzhen Mindray and its concerted parties rose to 37.4182 million [1] - **Regulatory Compliance** - The share acquisition complies with relevant laws and regulations [1] - The increase in shareholding will not result in a change of control for the company [1]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][41]. Core Views - The pharmaceutical sector has shown resilience, outperforming the overall market with a 1.40% increase, while the total A-share market declined by 1.17% [1][32]. - ANGPTL3 has gained significant interest from multinational pharmaceutical companies (MNCs) due to its unique mechanism of action, which is non-LDLR dependent, making it effective in patients with LDLR deficiencies [3][30]. - The report highlights the diverse drug forms targeting ANGPTL3, with MNCs like Novartis, Lilly, Amgen, and AstraZeneca actively investing in this area, indicating a potential for multi-target and multi-drug combinations in the future [3][16]. Summary by Sections Market Performance - The overall A-share market fell by 1.17%, with the Shanghai and Shenzhen 300 index down by 0.81%. The biotechnology sector, however, rose by 1.40%, indicating strong performance relative to the broader market [1][32]. - Specific segments within the pharmaceutical sector showed varied performance, with chemical pharmaceuticals up by 3.92% and medical services up by 1.69%, while medical devices and traditional Chinese medicine saw declines [1][32]. ANGPTL3 Developments - A collaboration between Argo Biopharma and Novartis was announced, focusing on RNA drugs for cardiovascular diseases, with a total potential payment of $5.2 billion, including a $160 million upfront payment [2][11]. - ANGPTL3's mechanism allows for significant reductions in LDL-C levels in patients with HoFH, outperforming traditional treatments like PCSK9 inhibitors [3][31]. Company Earnings Forecasts and Ratings - Key companies in the sector, such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, have been rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion yuan [4][41]. - The report provides detailed earnings forecasts for various companies, indicating a positive outlook for the sector as a whole [4][41]. Valuation Metrics - The TTM price-to-earnings ratio for the pharmaceutical and biotechnology sector stands at 40.75x, significantly higher than the overall A-share market's 19.80x [37][38]. - Sub-sectors such as chemical pharmaceuticals and biological products have even higher valuations, indicating strong investor interest and growth potential [37][38]. Recommended Stocks - The report recommends several companies, including Mindray Medical for its strong market position and international expansion, WuXi AppTec for its comprehensive drug development services, and Aier Eye Hospital for its leading position in the eye care sector [41][42].

Core Insights - The company reported a strong performance in H1 2025, with revenue of 1.214 billion yuan, a year-on-year increase of 21.26%, and a net profit attributable to shareholders of 425 million yuan, up 24.11% [1][2] Business Performance - The electrophysiology segment generated revenue of 246 million yuan, growing by 9.98%, with a gross margin of 75.13% [2] - The coronary intervention segment saw revenue of 654 million yuan, an increase of 30.02%, with a gross margin of 73.87% [2] - Peripheral intervention revenue reached 213 million yuan, up 21.33%, with a gross margin of 77.15% [2] - Non-vascular intervention revenue was 23 million yuan, growing by 39.68%, with a gross margin of 61.70% [2] - The overall gross margin for Q2 2025 was 73.87%, reflecting a year-on-year increase of 0.52 percentage points, driven by factors such as increased localization of raw materials and improved production automation [2] Product and Market Development - Electrophysiology procedures showed steady growth, with nearly 8,000 procedures completed in H1 2025, including over 800 PFA pulse ablation procedures [3] - The company hosted over 80 brand promotion events across more than 20 provinces, enhancing brand recognition and market penetration [3] - Domestic revenue reached 1.07 billion yuan, a 20.93% increase, while overseas revenue was 143 million yuan, up 23.84% [4] - The overseas self-owned brand revenue grew by 34.56%, with significant performance in Europe, Russia, and Latin America [4] Future Outlook - Revenue projections for 2025-2027 are estimated at 2.624 billion, 3.348 billion, and 4.274 billion yuan, with year-on-year growth rates of 27.0%, 27.6%, and 27.7% respectively [4] - Net profit forecasts for the same period are 883 million, 1.159 billion, and 1.500 billion yuan, with growth rates of 31.1%, 31.4%, and 29.4% respectively [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资者可于2025年9月10日（星期三）至9月16日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱ir@aptmed.com进行提问。公司将在本次业绩说明会上对投资者普 遍关注的问题进行回答。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）已于2025年8月22日发布《2025年半年度报告》， 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年9月17 日（星期三）15:00-17:00参加2025年半年度科创板医疗器械及医疗设备行业集体业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络文字互动形式召开，公司将针对2025年半年度的经营成果及财务指标的具体情况 与投资者进行互动交流，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 证券代码：688617 证券简称：惠 ...

深圳惠泰医疗器械股份有限公司 证券代码：688617 证券简称：惠泰医疗 公告编号：2025-043 关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 17 日（星期三）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@aptmed.com 进行提问。公司将在本次业绩说明会上对投资者普遍关注的问题 进行回答。 深圳惠泰医疗器械股份有限公司（以下简称"公司"）已于 2025 年 8 月 22 日发布《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 ...

Core Viewpoint - 惠泰医疗's stock price has shown a positive trend this year, with a year-to-date increase of 21.64%, indicating strong market performance and investor interest [1][2]. Financial Performance - For the first half of 2025, 惠泰医疗 reported a revenue of 1.214 billion yuan, representing a year-on-year growth of 21.26% [2]. - The net profit attributable to shareholders for the same period was 425 million yuan, reflecting a year-on-year increase of 24.11% [2]. Shareholder Information - As of June 30, 2025, 惠泰医疗 had 4,507 shareholders, an increase of 20.12% from the previous period [2]. - The average number of circulating shares per shareholder was 31,287, which is a 20.92% increase compared to the last period [2]. Dividend Distribution - 惠泰医疗 has distributed a total of 514 million yuan in dividends since its A-share listing, with 413 million yuan distributed over the past three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include 华夏上证科创板50成份ETF, holding 4.6347 million shares, an increase of 1.3341 million shares from the previous period [3]. - Other notable shareholders include 香港中央结算有限公司 and 易方达上证科创板50ETF, with increases in their holdings as well [3]. Market Activity - On September 9, 惠泰医疗's stock price decreased by 2.02%, trading at 310.88 yuan per share, with a total market capitalization of 43.838 billion yuan [1]. - The stock experienced a net outflow of 5.5892 million yuan in principal funds, indicating some selling pressure [1].

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Core Viewpoint - Shenzhen Huatai Medical (688617) has seen a recent increase in shareholding by its controlling shareholder, Shenzhen Mindray Technology Holdings Co., Ltd. (Mindray), which has raised its stake to 25.00% through a block trade [3][4][5]. Trading Information Summary - As of September 5, 2025, Huatai Medical's stock closed at 309.44 CNY, up 1.82%, with a turnover rate of 1.25%, trading volume of 17,600 lots, and a transaction value of 548 million CNY [1]. - On the same day, the net inflow of main funds was 64.10 million CNY, while retail and speculative funds saw net outflows of 2.29 million CNY and 61.81 million CNY, respectively [2][6]. Company Announcement Summary - Mindray increased its holdings in Huatai Medical by 655,536 shares, representing 0.46% of the total share capital, at a price of 248.20 CNY per share. Following this transaction, Mindray and its concerted party, Zhuhai Tongsheng Investment Partnership, hold a combined total of 35,253,449 shares, or 25.00% of the total share capital [3][4][5]. - The funding for this acquisition came from Mindray's own or self-raised funds, and it does not involve any funds from the company or its related parties [4][5]. Detailed Equity Change Report - The detailed equity change report indicates that the total transaction value for the shares acquired by Mindray was approximately 162.70 million CNY [5]. - The report confirms that this equity change does not lead to any change in the controlling shareholder or actual controller of the company, maintaining the company's independence and avoiding any adverse effects on related transactions [3][4][5].

Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].